Analysis firm names two Novo Nordisk drugs in 2023 top sales growth prediction
Evaluate Vantage has come out with a list of predictions for the biggest 2023 growth engines when it comes to pharma products.
by christian bundgaard, translated by daniel pedersen
With Wegovy on additional markets, Novo Nordisk is expected to increase its top line in 2023, reports Endpoints News citing analysis firm Evaluate Vantage.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
All Wegovy dose strengths are back on US market
For subscribers
.jpg&w=384&q=75)
